Category Archives: Biotechnology

You should read the following discussion and analysis of our financial conditionand results of operations together with our unaudited condensed consolidatedfinancial statements and the related notes included elsewhere in this QuarterlyReport and our audited consolidated financial statements and notes thereto andthe related Management's Discussion and Analysis of Financial Condition andResults of Operations included as part of our Annual Report on Form 10-K asfiled with the SEC on March 16, 2022 (2021 Annual Report). This discussion andanalysis and other parts of this Quarterly Report contain forward-lookingstatements that are based upon current beliefs, plans and expectations relatedto future events and our future financial performance that involve risks,uncertainties, and assumptions, such as statements regarding our intentions,plans, objectives, and expectations for our business. Our actual results and thetiming of selected events could differ materially from those described in orimplied by these forward-looking statements as a result of numerous factors,including those set forth in the section titled "Risk Factors." See also thesection titled "Special Note Regarding Forward-Looking Statements."

Overview

range of therapeutic areas. We are in the early stages of development across abroad pipeline of product candidates, all of which are currently in thepreclinical stage of development and are summarized below:

COVID-19 business update

Acquisitions

License and collaboration agreements

Success payments and contingent consideration

Cobalt success payment and contingent consideration

Components of operating results

Operating expenses

Research and development

Research and development related success payments and contingent consideration

General and administrative

Results of operations

Comparison of the three months ended March 31, 2022 and 2021

Research and development expenses

The following table summarizes the components of our research and developmentexpenses for the periods presented:

$ 41,880 $ 30,809

an increase of $11.2 million in personnel-related expenses, including an

increase in non-cash stock-based compensation of $3.0 million, which was

an increase of $9.1 million in research, development, and laboratory

costs, including third-party manufacturing costs, laboratory supplies, and

other external research expenses;

an increase of $5.3 million in facility and allocated costs, including

an increase of $4.9 million related to licensing technology for our CD22

and BCMA programs.

Research and development related success payments and contingent consideration

$ 127,050 $ (182,488 )

General and administrative Expenses

Liquidity, capital resources, and capital requirements

Sources of liquidity

Future funding requirements

Our future capital requirements will depend on many factors, including:

the scope, timing, progress, costs, and results of discovery, preclinical

the number and scope of clinical trials required for regulatory approval

of our current or future product candidates;

the costs, timing, and outcome of regulatory review of our current or

future product candidates;

the cost associated with building our manufacturing capabilities, as well

as costs associated with the manufacturing of clinical and commercial

supplies of our current and future product candidates;

the costs and timing of future commercialization activities, including

manufacturing, marketing, sales, and distribution, for any of our product

applications, maintaining and enforcing our intellectual property rights,

and defending any intellectual property-related claims, including any

claims by third parties that we are infringing upon their intellectual

collaborations, licensing, or other arrangements and the financial terms

of any such agreements, including the timing and amount of any future

milestone, royalty, or other payments due under any such agreement;

the revenue, if any, received from commercial sales of our product

our ability to establish a commercially viable pricing structure and

obtain approval for coverage and adequate reimbursement from third-party

and government payors;

potential interruptions or delays resulting from factors related to the

the extent to which we acquire or invest in businesses, products, and

technologies.

Cash flows

The following table summarizes our cash flows for the periods indicated:

Financing activities

Contractual obligations and commitments

The following table summarizes our significant contractual obligations andcommitments as of March 31, 2022:

Off-balance sheet arrangements

Since our inception, we have not engaged in any off-balance sheet arrangementsas defined under the rules and regulations of the SEC.

JOBS Act accounting election

Critical accounting policies and significant judgements and estimates

--------------------------------------------------------------------------------

Edgar Online, source Glimpses

Originally posted here:
SANA BIOTECHNOLOGY, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com

BioNEST caters to biotech entrepreneurs, startups with access to relevant instruments, offers mentorship, access to experts, angels, and regulatory guidance

BioNEST caters to biotech entrepreneurs, startups with access to relevant instruments, offers mentorship, access to experts, angels, and regulatory guidance

A Bioincubators Nurturing Entrepreneurship for Scaling Technologies (BioNEST) facility was inaugurated at Manipal Academy of Higher Education (MAHE) in Manipal, Udupi district of Karnataka, on April 29.

BioNEST is supported by Biotechnology Industry Research Assistance Council (BIRAC) of the Department of Biotechnology. BioNEST is a dedicated scheme of BIRAC that supports the creation of globally competent bioincubation facilities across India. The scheme supports specialised incubation centres to cater to biotech entrepreneurs, startups with access to relevant instruments, offers mentorship, access to experts, angels, and regulatory guidance. This scheme is aligned with national mission programmes such as Startup India and Make in India.

The facility at MAHE promotes technology innovations for the development of knowledge-based enterprise with successful business models. Bioincubator provides world class faculty, infrastructure and services for incubation of start-ups in various domains of biopharma, biomedical devices, dental innovation, biotechnology, healthcare and diagnostics sectors.

The facility is spread over 10,000 sq. ft. and located at the heart of MAHE. it consists of dedicated and shared laboratories, offices, well-equipped instrumentation electronics testing facility, FAB laboratories, microfluidic laboratory, co-working space, office spaces, board room, meeting rooms, cafeteria and other amenities.

In addition, MAHE supports incubates with access to central equipment facilities, mentors and experts. BioNEST provide various services in technology management, IP management, technology transfer, business plan development, prototype development, refinement, grants support assistance and market evaluation of innovative technology ideas.

The facility was inaugurated by Ranjan R Pai, Chairman, Manipal Education and Medical Group (MEMG), Bengaluru during an event attended by Manish Diwan, DGM & Head - Strategy Partnership & Entrepreneurship Development, BIRAC, Delhi; H. S. Ballal, Pro Chancellor, MAHE, and M. D. Venkatesh, Vice Chancellor.

Visit link:
BioNEST facility opened at MAHE in Manipal for biotechnology start-ups - The Hindu

Biotechnology is a wide discipline that harnesses cellular and biomolecular processes to develop technologies that help in improving the health and lives of the people.

Biotechnology is the field that exploits living organisms to make technological advances in various fields for the sustainable development of mankind. It has its applications in the medical as well as agricultural sectors. The biological processes of living organisms have been used for more than 6000 years to make essential products such as bread, cheese, alcohol, etc.

Let us have a look at the various types and applications of biotechnology in various fields.

Also Read: Biotechnology Principles

Biotechnology is divided into the following types:

Medical biotechnology involves the use of living cells to develop technologies for the improvement of human health. It involves the use of these tools to find more efficient ways of maintaining human health. It also helps in the study of DNA to identify the causes of genetic disorders and methods to cure them.

Vaccines and antibiotics have been developed with the help of medical biotechnology that is essential for human health. Several plants are genetically engineered to produce antibodies with the help of biotechnology.

This field deals with the development of genetically modified plants by introducing the gene of interest in the plant. This, in turn, helps in increasing the crop yield.

Various pest-resistant crops such as Bt-cotton and Bt-brinjal are created by transferring the genes from Bacillus thuringiensis into the plants.

The animals with the most desirable characteristics are bred together to obtain the offspring with the desired traits.

Also Read: Biotechnology Principles and Processes

Following are the important applications of biotechnology:

Nutrients can be infused into food in situations of aid. e.g., Golden rice is prepared by the infusion of beta-carotene into the rice.

Biotechnology helps in the production of crops that can handle abiotic stress such as cold, drought, salinity, etc. In the regions with extreme climatic conditions, such crops have proved beneficial in withstanding the harsh climate.

Biotechnology involves the production of alcohol, detergents, cosmetic products, etc. It involves the production of biological elements and cellular structures for numerous purposes.

Spider webs have materials with the strongest tensile strength. The genes from the spiders have been picked up through biotechnological techniques and infused in goats to produce silk proteins in their milk. This helps in the production of silk easily.

Biotechnology is widely used in energy production. Due to the depletion of natural resources, there is a need to find an alternative source. Such fuels are produced by using biotechnology tools. These are environment friendly and do not release any greenhouse gas.

Biotechnology is applied in the development of pharmaceuticals that had proven problematic when produced through conventional means due to purity concerns.

Also Read: Applications Of Biotechnology

This is how biotechnology is a boon to society. To know more about biotechnology class 12 topics such as what is biotechnology, its types and applications, keep visiting BYJUS website or download BYJUS app for further reference.

See original here:
Biotechnology - Types And Applications Of Biotechnology

BURLINGTON, Vt. -- The former owner of two Vermont ski resorts was sentenced Friday to five years in prison for his role in a failed plan to build a biotechnology plant using tens of millions of dollars in foreign investors money.

The sentencing of Ariel Quiros, former owner of Jay Peak and Burke Mountain, wraps up the largest fraud case in Vermont history.

During the hearing, prosecutors told U.S. District Judge Geoffrey Crawford that Quiros, 65, kept for himself an estimated $30 million to $37 million that had been intended for the construction of the biotechnology plant in Newport, near the Canadian border.

This project was a fiction from beginning to end, Crawford said during the sentencing hearing.

The financial scandal involving Quiros and two others shook the state and its rural, economically depressed region called the Northeast Kingdom. A fourth man, a businessman in South Korea, remains at large.

Prior to being sentenced, Quiros apologized for his actions.

I deeply regret being involved in this case, Quiros said.

Prosecutors described Quiros, a Miami businessman who now lives in Puerto Rico, as a wheeler-dealer who played a role in the larger scheme.

The crimes could not have occurred without the toxic mix of these three mens strong personalities, Assistant U.S. Attorneys Paul van de Graaf and Nicole Cate wrote in their sentencing document.

Quiros, former Jay Peak president William Stenger and Quiros adviser William Kelly were indicted in 2019 over the failed plan to build the AnC Bio plant using millions of dollars raised through a visa program that encourages foreigners to invest in job-creating ventures in the U.S. in exchange for a chance to earn permanent residency.

Quiros pleaded guilty in August 2020 to charges of conspiracy to commit wire fraud, money laundering and the concealment of material information related to the AnC project. Other charges were dropped.

In a news release distributed after the sentencing, prosecutors said that Quiros admitted that he and his co-conspirators misled AnC investors about important information, including how investor money would be used and the timing of the required job creation for the project.

Stenger, of Newport, and Kelly, of Fort Lauderdale, Florida, were each sentenced this month to 18 months in prison, with Stenger ordered to pay $250,000 and Kelly to pay $8.3 million in restitution.

Prosecutors asked the judge to sentence Quiros to less than the eight-year maximum under the plea deal, based on his cooperation and acceptance of responsibility. The defense had asked for 18 months of home confinement, citing his cooperation, military service and wifes health problems.

Prosecutors said the project was designed to raise $110 million from 220 investors to build and operate the biotechnology facility, according to court records and proceedings. About 170 investors put in at least $500,000 each for a total of about $85 million between 2012 and 2016, but the project was never built, prosecutors said.

Three years before Quiros and Stenger were charged, the federal Securities and Exchange Commission and the state of Vermont alleged in 2016 that they took part in a massive eight-year fraudulent scheme. The civil allegations involved misusing more than $200 million of about $400 million raised from foreign investors for various ski area developments through the same visa program in Ponzi-like fashion.

Quiros and Stenger settled civil charges with the SEC, with Quiros surrendering more than $80 million in assets, including the two resorts.

Prosecutors wrote in their sentencing recommendation in the criminal case that Quiros relied on Kelly and Stenger to address details, with Stenger acting as fundraiser and the face of the biotechnology plant project, and Kelly carrying out his wishes and fix problems.

Quiros was more interested in profits than details and perceived that these professionals gave him cover, prosecutors wrote. He wanted the gravy train to keep rolling, if possible, they wrote.

Quiros' lawyer wrote that Quiros has overwhelmingly displayed his contrition and desire to make amends, has taken full responsibility for his conduct and demonstrated remorse substantially.

Associated Press writer Wilson Ring in Burlington contributed to this report.

Originally posted here:
Former ski resort owner gets 5 years in Vermont fraud case - ABC News

Scott McVey, president of Millig Design Build, an expert in decarbonization, to speak at ISPE Biotechnology Conference.

"It's an honor to be invited to deliver this presentation at the ISPE Biotechnology Conference," said McVey. "The biopharmaceutical sector has bold, ambitious carbon reduction targets. This event is the perfect opportunity to share specific steps the industry can take now to achieve its Net Zero goals."

McVey's presentation will focus on the challenges the biopharmaceutical sector faces in achieving Net Zero carbon emissions; the technologies available today that can safely replace the fossil fuels the industry uses for electricity and manufacturing processes; and the steps the sector needs to take now to achieve Net Zero by 2050.

Unlike the majority of the manufacturing sector, where most energy consumption comes from process heat, 65 percent of energy consumption in the biopharmaceutical sector arises from stringent environmental conditioning requirements like indoor temperature, relative humidity, air change rate, room pressurization, filtration, and ventilation. Millig Design Build has developed a sequence strategy the biopharmaceutical sector can deploy to meet stringent environmental conditioning requirements and ensure safety and quality, while reducing Scope 1 and 2 carbon emissions associated with electricity and fuel use.

"As a design-build firm, Millig is uniquely positioned to decarbonize critical environments like those found in biopharmaceutical facilities," said McVey. "We deliver value far beyond a decarbonization plan. We provide an actionable roadmap for long-term decarbonization, and we're able to immediately design and install the solutions we identify during our initial analysis phase."

About Millig Design BuildMillig Design Build is an integrated engineering, design, and construction firm specializing in facility improvements that address energy efficiency, building health and safety, and core infrastructure needs. Our mission is to create environments that promote sustainability, wellbeing, and opportunity for communities while efficiently delivering best-value solutions for owners. We have offices in Kansas; Colorado; Oregon; Washington; and Vancouver, Canada. For more information, visit http://www.milligdb.com.

Media Contact Information:Amy McVeyMillig Design BuildPhone: 785-865-6054E-mail: [emailprotected]

SOURCE Millig Design Build

Go here to see the original:
Millig Design Build President is Speaker at 2022 ISPE Biotechnology Conference on Sustainability in the Biopharmaceutical Industry - PR Newswire

Marketreports.info has presented a Global Biotechnology Algae Cultivation Process (Micro Algae) Market from 2022 to 2030 global study report that contains a market overview, practical solutions, and cutting-edge technologies to improve consumer awareness. The Biotechnology Algae Cultivation Process (Micro Algae) study offers an in-depth analysis of the current market scenario as well as details on the key trends, risks, and challenges that have a significant influence on market revenue. The research covers the global Biotechnology Algae Cultivation Process (Micro Algae) market, as well as emerging trends, product usage, customer and competitors motivating factors, marketing strategy, and customer perception.

This study offers an in-depth investigation of the Biotechnology Algae Cultivation Process (Micro Algae) market, along with Biotechnology Algae Cultivation Process (Micro Algae) market shares and development opportunities by type of product, application, company, major regions, and predictions for 2022 to 2030. Based on the current report, the global Biotechnology Algae Cultivation Process (Micro Algae) market is expected to grow at a significant rate, based on current trends and research.

DOWNLOAD FREE SAMPLE Biotechnology Algae Cultivation Process (Micro Algae) REPORT: marketreports.info/sample/21826/Biotechnology-Algae-Cultivation-Process-(Micro-Algae)

The global Biotechnology Algae Cultivation Process (Micro Algae) market study needs a detailed overview of regions, positions, growth rates, and market share players. The following are the markets leading corporations:

Cellana, DENSO, Ecoduna, Solix Biofuels, Sapphire Energy, Algenol Biofuels, LGem, Solazyme, Cyanotech, Seambiotic, Mialgae, Neoalgae

Segmentation covered in this Biotechnology Algae Cultivation Process (Micro Algae) report are:

By TypeEuglenophyta (Euglenoids)Chrysophyta (Golden-Brown Algae and Diatoms)Pyrrophyta (Fire Algae)Chlorophyta (Green Algae)Rhodophyta (Red Algae)Paeophyta (Brown Algae)Xanthophyta (Yellow-Green Algae)OthersBy ApplicationFoodFertilizer and AgarPollution ControlEnergy Production

The significant geographies included in the global Biotechnology Algae Cultivation Process (Micro Algae) market study are:

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

ACCESS FULL Biotechnology Algae Cultivation Process (Micro Algae) REPORT: marketreports.info/industry-report/21826/Biotechnology-Algae-Cultivation-Process-(Micro-Algae)

The research covers the global Biotechnology Algae Cultivation Process (Micro Algae) markets growth potential and categorizes it by type, applications, and geography. The research provides a substantial basis for organizations who want to enter the global Biotechnology Algae Cultivation Process (Micro Algae) market in terms of drivers, constraints, opportunities, and competitor analysis. The Biotechnology Algae Cultivation Process (Micro Algae) market study examines the markets size, participants, recent events, and significant market changes.

Customization of the Biotechnology Algae Cultivation Process (Micro Algae) Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketreports.info), who will ensure that you get a report that suits your needs. You can also get in touch with our executives directly to share your research requirements.

About Us

Marketreports.info is a global market research and consulting service provider specialized in offering wide range of business solutions to their clients including market research reports, primary and secondary research, demand forecasting services, focus group analysis and other services. We understand that how data is important in today's competitive environment and thus, we have collaborated with industry's leading research providers who works continuously to meet the ever-growing demand for market research reports throughout the year.

Contact Us:

CarlAllison (Head of Business Development)

Tiensestraat 32/0302,3000 Leuven, Belgium.

Market Reports

phone:+44 141 628 5998

Email: sales@marketreports.info

Website: http://www.marketreports.info

See the article here:
Biotechnology Algae Cultivation Process (Micro Algae) Market Key Trends And Opportunity Areas themobility.club - themobility.club

The latest research study published by SMI, the Biotechnology Reagents Market report evaluates the current market size and describes necessary factors like prime manufacturers, production worth, market share, key regions, and growth rate. It also focuses more on current statistics on the global Biotechnology Reagents industry. The report provides a detailed assessment of the key market dynamics and a qualitative analysis of the structure of the Biotechnology Reagents industry. The report covers the crucial parts of the Biotechnology Reagents market and such factors as driving forces, current trends, economic scenarios, and technological innovations.

Click here to get the sample PDF of the premium report: https://www.stratagemmarketinsights.com/sample/126657

Competitive Landscape:

A full overview of the major market players and contributors was briefly presented in the report to address different questions from customers and readers. Prominent players & their production data, percentage splits, market shares, product industry breakdowns, and growth rates are analyzed through secondary and validated primary sources.

Top Manufacturers of this Report:

Life Technologies, (U.S.), Bio-Rad (U.S.), Thermo Fisher Scientific (U.S.), Water Corporation (U.S.), Sigma-Aldrich (U.S.), Agilent Technologies Inc. (U.S.), Betcon Dickinson (U.S.), Beckman Coulter (U.S.), Roche (Switzerland), Abbott (U.S.)

Scope and Segmentation Analysis:

The Biotechnology Reagents market report covers specific market segments based on manufacturers, regions, types, and applications. The Biotechnology Reagents market report gives a clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macroeconomic, and governing factors in the market.The Biotechnology Reagents market report will facilitate business owners to comprehend the current trend of the market and make profitable decisions.

Segments by Type:

Life science, Analytical

Segments by Applications:

Protein synthesis and purification , Gene expression , DNA and RNA analysis , Drug testing

Research Methodology:

The research methodology is comprised of four steps namely secondary research, primary research, market estimation, and final presentation. At the inception of secondary research, extensive data is collected, which is refined and verified with reliable sources. The primary research starts with the validation of data processed in the secondary research.

Get Detailed Analysis and Enquiry Before Buying onBiotechnology Reagents Market @ https://www.stratagemmarketinsights.com/quiry/126657

Major Highlights of the Report:

It provides niche insights for the decision about every possible segment helping in the strategic decision-making process.

Market size estimation of the Biotechnology Reagents Market on a regional and global basis.

A unique research design for market size estimation and forecast from 2022 to 2028.

Identification of major companies operating in the market with related developments.

Exhaustive scope to cover all the possible segments helping every stakeholder in the Biotechnology Reagents market.

The key areas of operation for the global Biotechnology Reagents Market are:

Regional assessment of the Biotechnology Reagents market has been carried out over six key regions which include North America, Asia-pacific, Europe, Latin America, Middle East, and Africa. Moreover, the report also delivers deep insights on the ongoing research & development activities, revenue, innovative services, the actual status of demand and supply, and pricing strategy.

* North America (United States, Canada and Mexico)* Europe (Germany, France, United Kingdom, and Rest of Europe)* Asia-Pacific (Japan, Korea, India, Southeast Asia, and Australia)* South America (Brazil, Argentina, and Rest of South America)* Middle East & Africa (Saudi Arabia, UAE, Egypt, and Rest of Middle East & Africa)

What Report Exactly Offers to the Buyers?

1. A comprehensive overview of the global Biotechnology Reagents market.2. Detailed information on factors that will fuel or hamper market growth prospects for the global market.3. Potential market CAGR projections over the forecast period.4. Precise market size estimations of the Biotechnology Reagents industry.5. Accurate upcoming trends and consumer behavior pattern predictions.6. Potential expansion prospects for the Biotechnology Reagents market.

Interested in Procuring this Report? Visit Here: https://www.stratagemmarketinsights.com/cart/126657

Contact Us:

Mr. ShahStratagem Market Insights1001 4th Ave, #3200 Seattle, WA 98154Phone: US +12067016702 / UK +4402081334027 / JAPAN +815055391737Email: sales@stratagemmarketinsights.com

VB

Read more from the original source:
Biotechnology Reagents Market 2022: In-depth Growth Outlook, Development Trends, Demand Opportunities, and Regional Forecast by 2028 |Life...

Equities analysts expect Exelixis, Inc. (NASDAQ:EXEL Get Rating) to report sales of $378.80 million for the current quarter, Zacks reports. Six analysts have made estimates for Exelixis earnings, with the highest sales estimate coming in at $475.40 million and the lowest estimate coming in at $344.39 million. Exelixis posted sales of $270.23 million in the same quarter last year, which suggests a positive year over year growth rate of 40.2%. The company is expected to issue its next earnings report after the market closes on Monday, January 1st.

On average, analysts expect that Exelixis will report full-year sales of $1.69 billion for the current year, with estimates ranging from $1.53 billion to $2.01 billion. For the next financial year, analysts anticipate that the business will post sales of $1.92 billion, with estimates ranging from $1.84 billion to $2.09 billion. Zacks sales averages are an average based on a survey of research analysts that that provide coverage for Exelixis.

Exelixis (NASDAQ:EXEL Get Rating) last posted its quarterly earnings data on Thursday, February 17th. The biotechnology company reported $0.29 EPS for the quarter, topping the Thomson Reuters consensus estimate of $0.07 by $0.22. Exelixis had a return on equity of 11.17% and a net margin of 16.10%. The company had revenue of $451.14 million during the quarter, compared to analyst estimates of $357.17 million.

NASDAQ:EXEL opened at $22.34 on Friday. Exelixis has a 12 month low of $15.50 and a 12 month high of $25.77. The stock has a 50 day moving average of $21.75 and a two-hundred day moving average of $19.70. The firm has a market cap of $7.15 billion, a P/E ratio of 31.46, a price-to-earnings-growth ratio of 0.71 and a beta of 0.79.

In other Exelixis news, EVP Patrick J. Haley sold 60,000 shares of the companys stock in a transaction on Thursday, February 3rd. The stock was sold at an average price of $17.91, for a total transaction of $1,074,600.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Jack L. Wyszomierski sold 6,696 shares of the companys stock in a transaction on Monday, April 4th. The stock was sold at an average price of $23.00, for a total value of $154,008.00. Following the transaction, the director now owns 273,192 shares in the company, valued at $6,283,416. The disclosure for this sale can be found here. Insiders sold 205,229 shares of company stock worth $4,017,116 over the last quarter. 3.30% of the stock is currently owned by insiders.

Large investors have recently added to or reduced their stakes in the business. Jefferies Group LLC lifted its stake in Exelixis by 49.2% during the third quarter. Jefferies Group LLC now owns 69,000 shares of the biotechnology companys stock worth $1,459,000 after purchasing an additional 22,739 shares in the last quarter. BlackRock Inc. raised its stake in shares of Exelixis by 2.0% in the third quarter. BlackRock Inc. now owns 31,907,047 shares of the biotechnology companys stock valued at $674,514,000 after acquiring an additional 612,104 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Exelixis by 31.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 43,639 shares of the biotechnology companys stock valued at $798,000 after acquiring an additional 10,327 shares in the last quarter. Squarepoint Ops LLC raised its stake in shares of Exelixis by 32.7% in the third quarter. Squarepoint Ops LLC now owns 359,712 shares of the biotechnology companys stock valued at $7,604,000 after acquiring an additional 88,635 shares in the last quarter. Finally, LPL Financial LLC raised its stake in shares of Exelixis by 70.7% in the third quarter. LPL Financial LLC now owns 63,251 shares of the biotechnology companys stock valued at $1,337,000 after acquiring an additional 26,188 shares in the last quarter. Institutional investors own 82.80% of the companys stock.

About Exelixis (Get Rating)

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Featured Stories

Get a free copy of the Zacks research report on Exelixis (EXEL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Read more from the original source:
Exelixis, Inc. (NASDAQ:EXEL) Expected to Post Quarterly Sales of $378.80 Million - Defense World

DanielPrudek/iStock via Getty Images

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) is a healthcare exchange traded fund (ETF) launched by BlackRock, Inc. in June 2019, i.e., less than three years back. This ETF is managed by BlackRock Fund Advisors and has an Asset Under Management (AUM) of $209 million. It invests in public equity shares in all the major stock markets worldwide, with 60 percent investments in the US stock market. This ETF has around 11 percent investments in the Japanese stock market and 24 percent investments in European equity markets.

iShares Genomics Immunology and Healthcare ETF primarily invests in biotechnology and pharmaceutical stocks. It has also invested around 3 percent in a dividend fund, namely Eaton Vance Tax-Advantaged Dividend Income Fund (EVT). IDNA benchmarks the performance of its portfolio against the NYSE FactSet Global Genomics and Immuno Biopharma Index. This index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering.

iShares Genomics Immunology and Healthcare ETF is a relatively new ETF, launched less than three years ago, and is operating with an expense ratio of 0.47 percent. This ETF is not meant for income-seeking investors, as it intends to pay semi-annual dividends, but with a very low yield. The average year-end yield of the past three years has been less than 0.6 percent. Thus, the investment decision will solely depend upon the expected future performance of the fund over the long run.

iShares Genomics Immunology and Healthcare ETF has performed poorly over the past 12 months. IDNA has recorded a negative growth of around 9 percent, 40 percent, and 38 percent over the past three months, six months, and 12 months, respectively. We all know that the biotechnology sector had an extremely poor last six months in 2021. Still, for a growth-seeking ETF to generate a negative return of that high percentage may make the investors skeptical.

An analysis of IDNA's top 30 common equity holdings (holding 90 percent of the entire portfolio) reveals that most of its investments are in biotechnology stocks. Out of these 30 equities, 24 biotechnology stocks (22 are listed in the US stock market) are holding more than 60 percent of its total portfolio.

Only five stocks are from the pharmaceutical sector, holding around 26 percent of its total portfolio. Incidentally, all these five stocks are listed outside the United States. One of IDNA's top holdings (3.85 percent of total portfolio), Maravai LifeSciences Holdings, Inc. (MRVI), belongs to the life sciences tools & services industry.

Barring Regeneron Pharmaceuticals, Inc. (REGN), all the biotechnology and life science companies listed in the New York Stock Exchange (NYSE) have recorded negative price growth over the past 12 months. This explains the massive loss of IDNA's price over the past one year. Another company, Exelixis, Inc. (EXEL) recorded positive price growth over the past six months.

Another three stocks - Maravai LifeSciences Holdings, Inc., Iovance Biotherapeutics, Inc. (IOVA), and Genmab A/S (GMAB) - recorded double-digit positive growth in the past three months. Thus, this ETF seems to be slowly recovering from the steep downfall in the second half of 2021. Still, it has a long way to go, as 20 such companies are yet to recover themselves.

iShares Genomics Immunology and Healthcare ETF, however, has posted a price growth of 22 percent since its inception in June 2019. This suggests that this ETF has performed very well in the first two years of its operation, and the stocks included in this ETF are quite volatile. There are other genomic revolution funds like Invesco Dynamic Biotechnology & Genome Portfolio ETF (PBE), Global X Genomics & Biotechnology ETF (GNOM) and ARK Genomic Revolution ETF (ARKG), which also performed poorly last year. The similar trend is visible in most of the funds - huge price loss in the past 12 months, but positive price gain since June 2019 (the time when IDNA was launched).

Despite the market price falling by 61.1 percent in the past one year, ARKG registered a growth of 3.3 percent over the past three years. PBE's price also fell by 25.3 percent in the past one year but grew by 7.8 percent over the past three years. Only GNOM failed miserably and recorded a negative growth of 44.5 percent and 13.9 percent growth over the past one year and three years, respectively. During the same period, S&P 500 OTC:GREW by 4 percent and 53 percent, respectively.

Weighted average Price to Equity ratio of the component stocks of iShares Genomics Immunology and Healthcare ETF comes to around 14.29, compared to the index's Price to Equity ratio of 16.67. IDNA's Price to Book ratio is 2.23, compared to the index's Price to Book ratio of 3.98. This suggests that the ETF is slightly undervalued. This assumption gets further validation as the price/sales of 1.27, and price/cash flow of 9.7, is relatively lower than the index (Price/Sales of 1.64 and Price/Cash Flow of 13.35).

However, the iShares Genomics Immunology and Healthcare ETF is currently trading at only 3 percent premium over its 52-week low, and there is scope for a further downward rally of this fund, as indicated by the simple moving averages (SMA). The long-term moving averages of this fund are placed significantly higher than the short-term moving averages. As of 28th April 2022, the 200-day SMA (43.67), 100-day SMA (36.73), 50-day SMA (33.54) and 10-day SMA (31.82) are indicative of a bearish rally for this ETF.

Thus, there lies every possibility of stiff downward movement with every downward trend in the market. Moreover, being a theme-based biotechnology index fund, IDNA cannot overcome its inherent volatility and market risk, which may arise due to changes in investors' sentiment or any negative news about its constituent stocks or the sector as a whole. The possibility of most of the stocks in its portfolio generating positive returns will take time, maybe another six to nine months. However, a course correction for IDNA is very much possible, too, if the biotechnology sector gets some positive boost or gets into any bull run.

In my opinion, iShares Genomics Immunology and Healthcare ETF can only be considered as a medium or long-term investment option. Genomic revolution has good growth prospects, which may enable these biotechnology stocks to generate supernormal growth. Moreover, a few of the biotechnology stocks that IDNA holds have started generating positive returns. Besides, the pharmaceutical stocks listed in other equity markets have always maintained a good return.

The overall price growth since the inception of this fund is quite impressive, considering the huge impact of Covid-19 pandemic in the US equity market. Although the portfolio of investments is expected to generate positive return in the medium term, iShares Genomics Immunology and Healthcare ETF is a better prospect for long-term growth-seeking investors. However, it is advisable that such long-term growth seekers hedge themselves with put options, in order to protect their investments from likely downward movements, which may happen from time to time.

Visit link:
IDNA: A Long Term Prospect, Slowly Overcoming The Bearish Rally - Seeking Alpha

Request Information

Biotechnology is a swiftly growing industry. From the food grown at our farms to the medicine we buy and the ways we clean up the environment, biotechnology affects many facets of our daily lives. Major developments in the field occur every day, with many introduced by academic and professional communities before the greater public is even aware of industry advancements.

At the School of Engineering, youll join in these exciting discoveries. Course topics range from industrial application of enzymes and bio-polymer synthesis to modern drug design and the role of biotechnology in health care. The availability of various and varied electives enables you to specialize in selected biotechnology areas.

The program also includes Advanced Cell and Molecular Biology and Genetic Engineering courses, both with labs. Students can further enhance their research and analytical skills by registering for a Guided Study course. Taking two such courses will enable students to complete a body of research work equivalent to a master's thesis (optional). Students can also take a business- or management-related course from Biotechnology and Entrepreneurship M.S.

Other electives are available for both programs. For further details please visitBiotechnolgy, M.S. curriculum belowand theBiotechnology and Entrepreneurship, M.S. curriculum.

With advisors permission students can take courses at other Schools of NYU.

There are ample research/internship opportunities available at NYU and NYC at large. For example, many Biotech M.S. students participate in research projects at the NYU Langone Medical Center, the world-renowned Memorial Sloan Kettering Cancer Center, and other research institutions in the city. There are also internships in Biotech start-ups. All students can, of course, apply for summer internships at big pharmaceutical companies. To learn more about these opportunities see what our students say below.

Find outabout AdmissionRequirements.

What Our Students Say

See the rest here:
Biotechnology, M.S. | NYU Tandon School of Engineering